Regulation of aflatoxin B1-metabolizing aldehyde reductase and glutathione S-transferase by chemoprotectors.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Author(s): McLellan LI;McLellan LI; Judah DJ; Neal GE; Hayes JD
  • Source:
    The Biochemical journal [Biochem J] 1994 May 15; Vol. 300 ( Pt 1), pp. 117-24.
  • Publication Type:
    Journal Article; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Published by Portland Press on behalf of the Biochemical Society Country of Publication: England NLM ID: 2984726R Publication Model: Print Cited Medium: Print ISSN: 0264-6021 (Print) Linking ISSN: 02646021 NLM ISO Abbreviation: Biochem J Subsets: MEDLINE
    • Publication Information:
      Original Publication: London, UK : Published by Portland Press on behalf of the Biochemical Society
    • Subject Terms:
    • Abstract:
      Ingestion of aflatoxin B1 (AFB1) represents a major risk factor in the aetiology of human hepatocellular carcinoma. In the rat, the harmful effects of AFB1 can be prevented by the administration of certain drugs which induce hepatic detoxification enzymes. We have previously shown that treatment of rats with the chemoprotector ethoxyquin (EQ) results in a marked increase in expression of the Alpha-class glutathione S-transferase (GST) Yc2 subunit which has high activity towards AFB1-8,9-epoxide [Hayes, Judah, McLellan, Kerr, Peacock and Neal (1991) Biochem. J. 279, 385-398]. To allow an assessment of whether the increased expression of GST Yc2 represents a general adaptive resistance mechanism to chemical stress, that is invoked by both chemoprotectors and carcinogens, we have examined the effects of EQ, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), phenobarbital (PB), AFB1, 3-methylcholanthrene (3-MC) and clofibrate on the AFB1-glutathione-conjugating activity and the GST subunit levels in rat liver. In addition, the effect of these drugs on the hepatic levels of an aldehyde reductase (AFB1-AR) that metabolizes the cytotoxic dialdehydic form of AFB1 has been studied as this enzyme also appears to be important in chemoprotection. Administration of the antioxidants EQ, BHA or BHT, as well as PB, led to a marked increase in levels of the GST Yc2 subunit in rat liver, and this increase coincided with a substantial rise in the GST activity towards AFB1-8,9-epoxide; neither AFB1, 3-MC nor clofibrate caused induction of Yc2 or any of the GST subunits examined. Among the xenobiotics studied, EQ was found to be the most effective inducing agent for the Yc2 subunit as well as Yc1, Yb1 and Yf. However, PB was equally as effective as EQ in increasing levels of the Ya-type subunits, although it was not found to be as potent an inducer of the other GST subunits, including Yc2. In addition to induction of GST, EQ caused a substantial increase in the hepatic content of AFB1-AR. Both BHA and BHT were also able to induce this enzyme but, by contrast, PB was found to be a poor inducer of AFB1-AR. AFB1, 3-MC and clofibrate were unable to serve as inducers of this reductase. The presence of Alpha-class GST, including the Yc2 subunit, was examined in various rat tissues. Constitutive expression of Yc2 was found in the epididymis at levels comparable with that observed in the liver from EQ-treated rats.(ABSTRACT TRUNCATED AT 400 WORDS)
    • References:
      Biochem J. 1993 May 15;292 ( Pt 1):13-8. (PMID: 8503840)
      Biochem J. 1984 Dec 15;224(3):839-52. (PMID: 6543118)
      Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10350-4. (PMID: 8234296)
      Biol Reprod. 1982 May;26(4):559-65. (PMID: 7082727)
      Crit Rev Toxicol. 1985;15(2):109-50. (PMID: 3899519)
      Xenobiotica. 1987 Feb;17(2):127-37. (PMID: 3105185)
      Toxicol Appl Pharmacol. 1990 Sep 1;105(2):216-25. (PMID: 2120795)
      Cancer Res. 1958 May;18(4):469-77. (PMID: 13536999)
      Crit Rev Toxicol. 1988;19(2):113-45. (PMID: 3069332)
      Cancer Res. 1988 Sep 1;48(17):4776-82. (PMID: 3409219)
      Cancer Res. 1987 Oct 1;47(19):5218-23. (PMID: 2887284)
      Biochim Biophys Acta. 1990 Aug 17;1035(2):146-53. (PMID: 1697481)
      Carcinogenesis. 1981;2(5):457-61. (PMID: 6791858)
      Carcinogenesis. 1993 Apr;14(4):567-72. (PMID: 8472316)
      Biochem Biophys Res Commun. 1992 Oct 30;188(2):597-603. (PMID: 1445304)
      Carcinogenesis. 1992 Dec;13(12):2255-61. (PMID: 1473231)
      Biochem J. 1991 Jun 1;276 ( Pt 2):461-9. (PMID: 2049074)
      J Biol Chem. 1983 Feb 10;258(3):2052-62. (PMID: 6822548)
      Biochem J. 1989 Oct 15;263(2):393-402. (PMID: 2597111)
      Biochem Biophys Res Commun. 1983 Jul 29;114(2):813-21. (PMID: 6411093)
      J Biol Chem. 1991 Jun 25;266(18):11632-9. (PMID: 1646813)
      Biochem J. 1992 Aug 1;285 ( Pt 3):863-70. (PMID: 1386734)
      Cancer Res. 1989 Feb 15;49(4):951-7. (PMID: 2492210)
      Toxicol Appl Pharmacol. 1994 Mar;125(1):27-33. (PMID: 8128492)
      Arch Biochem Biophys. 1985 Aug 1;240(2):553-9. (PMID: 2411220)
      Pharmacol Ther. 1991;50(3):443-72. (PMID: 1754606)
      Biochem J. 1989 Sep 1;262(2):463-7. (PMID: 2803262)
      Carcinogenesis. 1987 May;8(5):631-6. (PMID: 3555880)
      Cancer Res. 1993 Sep 1;53(17):3887-94. (PMID: 8395332)
      Proc Natl Acad Sci U S A. 1990 Aug;87(16):6258-62. (PMID: 2166952)
      Biochem Pharmacol. 1986 May 15;35(10):1685-90. (PMID: 3707598)
      Biochem J. 1991 Oct 15;279 ( Pt 2):385-98. (PMID: 1953636)
      Biochem J. 1986 Aug 1;237(3):731-40. (PMID: 3800913)
      Cancer Res. 1985 Oct;45(10):5011-9. (PMID: 2862989)
      Biochem J. 1992 Jul 1;285 ( Pt 1):173-80. (PMID: 1637297)
      J Am Oil Chem Soc. 1975 Feb;52(2):59-63. (PMID: 805808)
      Biochem J. 1991 Jul 15;277 ( Pt 2):501-12. (PMID: 1859377)
      Proc Natl Acad Sci U S A. 1990 May;87(10):3826-30. (PMID: 2160079)
      Arch Biochem Biophys. 1993 Jun;303(2):383-93. (PMID: 8512323)
      Chem Res Toxicol. 1992 Jul-Aug;5(4):470-8. (PMID: 1391613)
      Biochem J. 1986 Feb 1;233(3):779-88. (PMID: 3707525)
      Anal Biochem. 1976 May 7;72:248-54. (PMID: 942051)
      Cancer Res. 1992 Jan 15;52(2):314-8. (PMID: 1728405)
      Carcinogenesis. 1984 Apr;5(4):473-7. (PMID: 6142773)
      Cancer Res. 1985 Jan;45(1):1-8. (PMID: 3880665)
    • Accession Number:
      0 (Anticarcinogenic Agents)
      0 (Isoenzymes)
      0 (Xenobiotics)
      1P9D0Z171K (Butylated Hydroxytoluene)
      25013-16-5 (Butylated Hydroxyanisole)
      56-49-5 (Methylcholanthrene)
      9N2N2Y55MH (Aflatoxin B1)
      9T1410R4OR (Ethoxyquin)
      EC 1.1.1.21 (Aldehyde Reductase)
      EC 2.5.1.18 (Glutathione Transferase)
      HPN91K7FU3 (Clofibrate)
      YQE403BP4D (Phenobarbital)
    • Publication Date:
      Date Created: 19940515 Date Completed: 19940628 Latest Revision: 20190501
    • Publication Date:
      20221213
    • Accession Number:
      PMC1138132
    • Accession Number:
      10.1042/bj3000117
    • Accession Number:
      8198522